Calciotropic and phosphaturic hormones in heart failure

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 11, 2016, Pages 971-979

  Zittermann, A ^a   Ernst, J B ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

1,25 dihydroxyvitamin D; Calcium; Fibroblast growth factor 23; Heart failure; Parathyroid hormone; Phosphate; Phosphorus; Vitamin D

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; VITAMIN D; 1,25-DIHYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCIUM INTAKE; FIBROBLAST GROWTH FACTOR; PHOSPHATE INTAKE;

ADULT; BLOOD VESSEL CALCIFICATION; CALCIUM INTAKE; CALCIUM METABOLISM; CONTROLLED CLINICAL TRIAL (TOPIC); ECHOCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INFANT; KIDNEY FUNCTION; META ANALYSIS (TOPIC); PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VITAMIN D DEFICIENCY; ADVERSE EFFECTS; AGE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIETARY SUPPLEMENT; FEMALE; KIDNEY DISEASES; MALE; SEDENTARY LIFESTYLE; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; BIOMARKERS; CALCIUM, DIETARY; DIETARY SUPPLEMENTS; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FAILURE; HUMANS; KIDNEY DISEASES; MALE; PHOSPHORUS, DIETARY; RISK FACTORS; SEDENTARY LIFESTYLE; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84992563886     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.06.007     Document Type: Review

References (61)

1. [1] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
2. [2] Strassburg, S., Anker, S.D., Metabolic and immunologic derangments in cardiac cachexia: where to from here?. Heart Fail Rev 11 (2006), 57–64.
3. [3] Roger, V.L., Weston, S.A., Redfield, M.M., Hellermann-Homan, J.P., Killian, J., Yawn, B.P., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004), 344–350.
4. [4] Zittermann, A., Schleithoff, S.S., Tenderich, G., Berthold, H.K., Körfer, R., Stehle, P., Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 41 (2003), 105–112.
5. (2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail 16 (2014), 1292–1300.
6. [6] Neubauer, S., The failing heart – an engine out of fuel. New Engl J Med 3566 (2007), 1140–1151.
7. [7] Holick, M.F., Vitamin D deficiency. N Engl J Med 357 (2007), 266–281.
8. [8] Jones, G., Strugnell, S.A., DeLuca, H.F., Current understanding of the molecular actions of vitamin D. Physiol Rev 78 (1998), 1193–1231.
9. [9] Hollis, B.W., Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am 39 (2010), 271–286.
10. [10] Razzaque, M.S., Phosphate toxicity and vascular mineralization. Contrib Nephrol 180 (2013), 74–85.
11. [11] Scialla, J.J., Wolf, M., Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10 (2014), 268–278.
12. [12] Docio, S., Riancho, J.A., Pérez, A., Olmos, J.M., Amado, J.A., González-Macías, J., Seasonal deficiency of vitamin D in children: a potential target for osteoporosis-preventing strategies?. J Bone Min Res 13 (1998), 544–548.
13. [13] Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96 (2011), 53–58.
14. [14] Laguardia, S.P., Dockery, B.K., Bhattacharya, S.K., Nelson, M.D., Carbone, L.D., Weber, K.T., Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 332 (2006), 112–118.
15. [15] Schierbeck, L.L., Jensen, T.S., Bang, U., Jensen, G., Køber, L., Jensen, J.E., Parathyroid hormone and vitamin D–markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 13 (2011), 626–632.
16. [16] Pilz, S., März, W., Wellnitz, B., Seelhorst, U., Fahrleitner-Pammer, A., Dimai, H.P., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93 (2008), 3927–3935.
17. [17] di Giuseppe, R., Buijsse, B., Hirche, F., Wirth, J., Arregui, M., Westphal, S., et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab 99 (2014), 947–955.
18. [18] Folsom, A.R., Alonso, A., Misialek, J.R., Michos, E.D., Selvin, E., Eckfeldt, J.H., et al. Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 168 (2014), 296–302.
19. [19] Zittermann, A., Schleithoff, S.S., Götting, C., Dronow, O., Fuchs, U., Kuhn, J., et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 10 (2008), 321–327.
20. [20] Zittermann, A., Fuchs, U., Kuhn, J., Dreier, J., Schulz, U., Gummert, J.F., et al. Parameters of mineral metabolism predict midterm clinical outcome in end-stage heart failure patients. Scand Cardiovasc J 45 (2011), 342–348.
21. [21] Gotsman, I., Shauer, A., Zwas, D.R., Hellman, Y., Keren, A., Lotan, C., et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 14 (2012), 357–366.
22. [22] Lip, G.Y., Skjøth, F., Overvad, K., Rasmussen, L.H., Larsen, T.B., Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. Clin Res Cardiol 104 (2015), 1088–1096.
23. [23] Vimaleswaran, K.S., Cavadino, A., Berry, D.J., LifeLines Cohort Study investigators, Jorde, R., Dieffenbach, A.K., et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol 2 (2014), 719–729.
24. [24] Heine, G.H., Mineral metabolism in heart disease. Curr Opin Nephrol Hypertens 24 (2015), 310–316.
25. [25] Pöss, J., Mahfoud, F., Seiler, S., Heine, G.H., Fliser, D., Böhm, M., et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2 (2013), 211–218.
26. [26] Zittermann, A., Morshuis, M., Kuhn, J., Pilz, S., Ernst, J.B., Oezpeker, C., et al. Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk. Eur J Nutr 55 (2016), 305–313.
27. [27] Rhee, H., Yang, J.Y., Jung, W.J., Shin, M.J., Yang, B.Y., Song, S.H., et al. Significance of residual renal function for phosphate control in chronic hemodialysis patients. Kidney Res Clin Pract 33 (2014), 58–64.
28. [28] Li, Y.C., Kong, J., Wei, M., Chen, Z.F., Liu, S.Q., Cao, L.P., 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 (2002), 229–238.
29. [29] Xiang, W., Kong, J., Chen, S., Cao, L.P., Qiao, G., Zheng, W., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288 (2005), E125–E132.
30. [30] Chen, S., Law, C.S., Grigsby, C.L., Olsen, K., Hong, T.T., Zhang, Y., et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124 (2011), 1838–1847.
31. [31] Schmidt, N., Brandsch, C., Kühne, H., Thiele, A., Hirche, F., Stangl, G.I., Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS One, 7, 2012, e35316.
32. [32] Zorbas, Y.G., Kakuris, K.K., Deogenov, V.A., Yerullis, K.B., Phosphate homeostasis in healthy subjects during prolonged periodic and continuous hypokinesia. Clin Biochem 40 (2007), 460–466.
33. [33] Zittermann, A., Sabatschus, O., Jantzen, S., Platen, P., Danz, A., Dimitriou, T., et al. Exercise-trained young men have higher calcium absorption rates and plasma calcitriol levels compared with age-matched sedentary controls. Calcif Tissue Int 67 (2000), 215–219.
34. [34] Scheld, K., Zittermann, A., Heer, M., Herzog, B., Mika, C., Drummer, C., et al. Nitrogen metabolism and bone metabolism markers in healthy adults during 16 weeks of bed rest. Clin Chem 47 (2001), 1688–1695.
35. [35] Gascon-Barré, M., D'Amour, P., Dufresne, L., Perreault, J.P., Interrelationships between circulating vitamin D metabolites in normocalciuric and hypercalciuric renal stone formers. Ann Nutr Metab 29 (1985), 289–296.
36. 3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 48 (1979), 1008–1016.
37. [37] Zittermann, A., Ernst, J.B., Birschmann, I., Dittrich, M., Effect of vitamin D or activated vitamin D on circulating 1,25-dihydroxyvitamin D concentrations: a systematic review and metaanalysis of randomized controlled trials. Clin Chem 61 (2015), 1484–1494.
38. [38] Pfeifer, M., Begerow, B., Minne, H.W., Nachtigall, D., Hansen, C., Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86 (2001), 1633–1637.
39. [39] Ferrari, S.L., Bonjour, J.P., Rizzoli, R., Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90 (2005), 1519–1524.
40. [40] Antoniucci, D.M., Yamashita, T., Portale, A.A., Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91 (2006), 3144–3149.
41. [41] Burnett, S.M., Gunawardene, S.C., Bringhurst, F.R., Jüppner, H., Lee, H., Finkelstein, J.S., Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Min Res 21 (2006), 1187–1196.
42. [42] Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70 (2006), 2141–2147.
43. [43] Sigrist, M., Tang, M., Beaulieu, M., Espino-Hernandez, G., Er, L., Djurdjev, O., et al. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transpl 28 (2013), 161–169.
44. [44] Andress, D.L., Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69 (2006), 33–43.
45. [45] Börgermann, J., Lazouski, K., Kuhn, J., Dreier, J., Schmidt, M., Gilis-Januszewski, T., et al. 1,25-Dihydroxyvitamin D fluctuations in cardiac surgery are related to age and clinical outcome. Crit Care Med 40 (2012), 2073–2081.
46. [46] Cashman, K.D., Dowling, K.G., Škrabáková, Z., Gonzalez-Gross, M., Valtueña, J., De Henauw, S., et al. Vitamin D deficiency in Europe: pandemic?. Am J Clin Nutr, 2016 Feb 10 pii: ajcn120873. [Epub ahead of print].
47. [47] Hallal, P.C., Andersen, L.B., Bull, F.C., Guthold, R., Haskell, W., Ekelund, U., et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 380 (2012), 247–257.
48. [48] Joy, M.S., Karagiannis, P.C., Peyerl, F.W., Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13 (2007), 397–411.
49. [49] Elidrissy, A.T., Munawarah, M., Alharbi, K.M., Hypocalcemic rachitic cardiomyopathy in infants. J Saudi Heart Assoc 25 (2013), 25–33.
50. [50] Shedeed, S.A., Vitamin D supplementation in infants with chronic congestive heart failure. Pediatr Cardiol 33 (2012), 713–719.
51. [51] Witte, K.K., Nikitin, N.P., Parker, A.C., von Haehling, S., Volk, H.D., Anker, S.D., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26 (2005), 2238–2244.
52. [52] Schleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R., Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83 (2006), 754–759.
53. [53] Witham, M.D., Crighton, L.J., Gillespie, N.D., Struthers, A.D., McMurdo, M.E., The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 3 (2010), 195–201.
54. [54] Boxer, R.S., Kenny, A.M., Schmotzer, B.J., Vest, M., Fiutem, J.J., Piña, I.L., A randomized controlled trial of high dose vitamin D3 in patients with heart failure. JACC Heart Fail 1 (2013), 84–90.
55. [55] Schroten, N.F., Ruifrok, W.P., Kleijn, L., Dokter, M.M., Silljé, H.H., Lambers Heerspink, H.J., et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J 166 (2013), 357–364.
56. [56] Dalbeni, A., Scaturro, G., Degan, M., Minuz, P., Delva, P., Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutr Metab Cardiovasc Dis 24 (2014), 861–868.
57. [57] Ford, J.A., MacLennan, G.S., Avenell, A., Bolland, M., Grey, A., Witham, M., et al. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 100 (2014), 746–755.
58. [58] Donneyong, M.M., Hornung, C.A., Taylor, K.C., Baumgartner, R.N., Myers, J.A., Eaton, C.B., et al. Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative. Circ Heart Fail 8 (2015), 49–56.
59. [59] Witte, K.K., Byrom, R., Gierula, J., Paton, M.F., Jamil, H.A., Lowry, J.E., et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. pii: S0735–1097(16)01694-6 J Am Coll Cardiol, 2016 Mar 24, 10.1016/j.jacc.2016.03.508 [Epub ahead of print].
60. [60] Standing committee on the scientific evaluation of dietary reference intakes. Food and nutrition Board. Institute of Medicine, Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. 1997, National Academy Press Washington D.C.
61. [61] Derungs, A., Drug-induced acute kidney injury. Ther Umsch 72 (2015), 717–727 [in German].